DNLI Denali Therapeutics Inc.

21.23
+0.26  (+1%)
Previous Close 20.97
Open 21
Price To Book 4.37
Market Cap 2015464278
Shares 94,957,092
Volume 106,177
Short Ratio
Av. Daily Volume 413,563

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b commencement of dosing announced December 10, 2018. Data due 4Q 2019.
DNL201
Parkinson’s disease
Phase 1 data presented December 2018.
DNL747
Alzheimer’s disease
Phase 1b commencement of dosing announced January 8, 2019. Data due 4Q 2019.
DNL747
Amyotrophic Lateral Sclerosis

Latest News

  1. New Research: Key Drivers of Growth for Walgreens Boots Alliance, Live Nation Entertainment, Denali Therapeutics, Haynes International, NV5 Global, and Johnson Outdoors — Factors of Influence, Major Initiatives and Sustained Production
  2. Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease
  3. Genentech kills big drug study in early Alzheimer's patients
  4. Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS
  5. Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
  6. The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
  7. Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics
  8. The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings
  9. Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi
  10. Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion — for a higher price
  11. The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal
  12. Where Dallas’ largest hedge funds are placing their long bets
  13. CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials
  14. Could Denali Therapeutics Inc’s (NASDAQ:DNLI) Investor Composition Impacts Your Returns?